DifGen Wins FDA IND Clearance for Breast Cancer Therapy
Miramar, Fla., July 27, 2026 DifGen Pharmaceuticals LLC has announced that the U.S. Food and Drug Administration (FDA) has...
ESMO 2026
Advertisement
Insilico Medicine Presents ISM6331 Phase 1 Data at ESMO
Cambridge, MA, July 27, 2026 Insilico Medicine has announced that first-in-human Phase 1 clinical trial data for ISM6331, its...
Immutep Announces ESMO 2026 Presentation for EFTISARC-NEO Trial
SYDNEY, Australia – July 24, 2026 Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO...
MacroGenics Reports Positive Phase 1 MGC026 Cancer Study Update
ROCKVILLE, MD, July 23, 2026 MacroGenics, Inc. announced a significant clinical update from its ongoing Phase 1 study of...
Can-Fite Phase 2a Namodenoson Pancreatic Cancer Data Accepted at ESMO 2026
RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...
Advertisements
GSK Seeks EMA Approval for Bexsero Booster Vaccine Update
LONDON, United Kingdom, July 20, 2026 GSK plc has announced that the European Medicines Agency (EMA) has accepted its...
BioLineRx to Present GLIX1 Ovarian Cancer Data at ESMO 2026
TEL AVIV, Israel & OSLO, Norway, July 20, 2026 BioLineRx Ltd. and Hemispherian AS have announced that new preclinical...
Almirall Seeks EMA Approval to Expand Ebglyss Use in Kids
BARCELONA, Spain, July 17, 2026 Almirall S.A. has announced that the European Medicines Agency (EMA) has accepted the Marketing...
Marengo Earns ESMO Oral Slot for Phase II Cancer Data
CAMBRIDGE, Mass., July 20, 2026 Marengo Therapeutics has announced that updated Phase II clinical data from its investigational immunotherapy...
IDEAYA Showcases Darovasertib Data at ESMO 2026
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
Advertisement
